Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, HIV Infections, Date of authorisation: 19/11/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Rezolsta, darunavir,cobicistat, HIV Infections, Date of authorisation: 19/11/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Multiple Myeloma, Date of authorisation: 21/11/2016, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Multiple Myeloma, Date of authorisation: 21/11/2016, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Leukemia, Myeloid, Date of authorisation: 06/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Leukemia, Myeloid, Date of authorisation: 06/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Exjade, deferasirox, beta-Thalassemia;Iron Overload, Date of authorisation: 28/08/2006, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Exjade, deferasirox, beta-Thalassemia;Iron Overload, Date of authorisation: 28/08/2006, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Esperoct, turoctocog alfa pegol, Hemophilia A, Date of authorisation: 20/06/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Esperoct, turoctocog alfa pegol, Hemophilia A, Date of authorisation: 20/06/2019, Revision: 6, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.